文献速递儿科与产科急症

印度高血压孕妇引产:Foley导尿管与口服米索前列醇比较(INFORM):多中心、开放标签、随机对照试验

Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial.
PubMed 文献 · Lancet · 2017-06-28
一句话结论对于妊娠20周及以上、因子痫前期或高血压需引产孕妇,口服米索前列醇25 μg每2小时(最多12剂)较经宫颈Foley导尿管引产提高24小时内阴道分娩率(57.0% vs 47.0%)。

INFORM为印度那格浦尔两家公立医院开展的多中心、开放标签、随机对照试验,纳入602名妊娠20周及以上、因子痫前期或高血压需引产的孕妇,1:1随机接受口服米索前列醇25 μg每2小时(最多12剂)或经宫颈Foley导尿管(硅胶18 F、30 mL球囊)引产。主要终点24小时内阴道分娩率在米索前列醇组高于Foley组(172/302 [57.0%] vs 141/300 [47.0%];绝对风险差10.0%,95%CI 2.0-17.9;p=0.0136)。子宫过度刺激发生率两组均低(2 [0.7%] vs 1 [0.3%];绝对风险差0.3%,95%CI -0.8至1.5;p=0.566),新生儿死亡无显著差异(6 [2.0%] vs 3 [1.0%];1.0,-1.04至2.97;p=0.322)。作者认为口服米索前列醇较经宫颈Foley导尿管引产更有效。

要点

  • 妊娠20周及以上、因子痫前期或高血压需引产的孕妇,口服米索前列醇25 μg每2小时(最多12剂)24小时内阴道分娩率57.0%,高于Foley导尿管组的47.0%(绝对风险差10.0%,95%CI 2.0-17.9;p=0.0136)。
  • 子宫过度刺激发生率米索前列醇组0.7%(2例) vs Foley组0.3%(1例),绝对风险差0.3%(95%CI -0.8至1.5;p=0.566),两组均低。
  • 新生儿死亡米索前列醇组2.0%(6例) vs Foley组1.0%(3例),差异无统计学显著(1.0,-1.04至2.97;p=0.322)。
  • Foley导尿管留置至活跃产程开始、导管脱落或满12小时;若12小时内未脱落,改用人工破膜加缩宫素(微滴重力输注装置)继续引产。
  • 研究期间报告17例严重不良事件(3%):Foley组产时惊厥1例、弥散性血管内凝血1例;围产期死亡10例(Foley组死产2例;新生儿死亡米索前列醇组5例、Foley组3例);新生儿疾病5例(出生窒息3例、败血症1例、新生儿惊厥1例)。

适用人群与场景

  • 纳入:年龄≥18岁、妊娠20周及以上、有活胎、因子痫前期或高血压需分娩的孕妇;场景为印度那格浦尔两家公立医院。

处置流程与药物剂量

  • 米索前列醇组:口服米索前列醇25 μg每2小时,最多12剂。
  • Foley导尿管组:经宫颈置入硅胶Foley导尿管(18 F,30 mL球囊),留置至活跃产程开始、导管脱落或满12小时;若12小时内未脱落,则行人工破膜并加用缩宫素,经微滴重力输注装置给药。
  • 两组均以间断听诊进行胎儿监测。

红旗征与不能漏的情况

  • 子宫过度刺激:米索前列醇组2例(0.7%)、Foley组1例(0.3%)。
  • 严重不良事件包括产时惊厥1例、弥散性血管内凝血1例(均发生在Foley组)。
  • 围产期死亡10例:Foley组死产2例;新生儿死亡米索前列醇组5例、Foley组3例。
  • 新生儿疾病5例:出生窒息3例、败血症1例、新生儿惊厥1例。

研究设计与关键结果

  • 研究类型:多中心、开放标签、随机对照试验;样本量602例(米索前列醇组302例、Foley组300例,意向性治疗人群);印度那格浦尔两家公立医院。
  • 干预与对照:口服米索前列醇25 μg每2小时(最多12剂) vs 经宫颈Foley导尿管(硅胶18 F、30 mL球囊)。
  • 主要终点:24小时内阴道分娩率米索前列醇组172/302(57.0%) vs Foley组141/300(47.0%);绝对风险差10.0%(95%CI 2.0-17.9;p=0.0136)。
  • 关键次要终点:子宫过度刺激米索前列醇组2例(0.7%) vs Foley组1例(0.3%);绝对风险差0.3%(95%CI -0.8至1.5;p=0.566)。新生儿死亡米索前列醇组6例(2.0%) vs Foley组3例(1.0%);1.0(95%CI -1.04至2.97;p=0.322),无显著差异。
  • 不良事件:研究期间报告17例严重不良事件(3%),包括产时惊厥1例、弥散性血管内凝血1例(均Foley组)、围产期死亡10例(Foley组死产2例;新生儿死亡米索前列醇组5例、Foley组3例)、新生儿疾病5例(出生窒息3例、败血症1例、新生儿惊厥1例)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照试验;因干预性质无法对受试者、研究者和照护者设盲;意向性治疗分析。
  • 局限:因干预性质无法设盲;作者结论指出未来研究需评估米索前列醇后缩宫素加强宫缩能否被规律剂量口服米索前列醇片替代。

对床旁实践的改变

  • 对于妊娠20周及以上、因子痫前期或高血压需引产的孕妇,口服米索前列醇25 μg每2小时(最多12剂)较经宫颈Foley导尿管引产提高24小时内阴道分娩率(57.0% vs 47.0%;绝对风险差10.0%,95%CI 2.0-17.9;p=0.0136)。
  • 两组子宫过度刺激发生率均低(米索前列醇组0.7% vs Foley组0.3%),新生儿死亡无显著差异(2.0% vs 1.0%;p=0.322)。
  • 作者认为口服米索前列醇较经宫颈Foley导尿管引产更有效;未来研究需评估米索前列醇后缩宫素加强宫缩能否被规律剂量口服米索前列醇片替代。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Between 62 000 and 77 000 women die annually from pre-eclampsia and eclampsia. Prompt delivery, preferably by the vaginal route, is vital for good maternal and neonatal outcomes. Two low-cost interventions-low-dose oral misoprostol tablets and transcervical Foley catheterisation-are already used in low-resource settings. We aimed to compare the relative risks and benefits of these interventions.

METHODS: We undertook this multicentre, open-label, randomised controlled trial in two public hospitals in Nagpur, India. Women (aged ≥18 years) who were at 20 weeks' gestation or later with a live fetus and required delivery as a result of pre-eclampsia or hypertension were randomly assigned (1:1), via computer-generated block randomisation (block sizes of four, six, and eight) with concealment by use of opaque, sequentially numbered, sealed envelopes, to receive labour induction with either oral misoprostol 25 μg every 2 h (maximum of 12 doses) or a transcervical Foley catheter (silicone, size 18 F with 30 mL balloon). Randomisation was stratified by study centre. The catheter remained in place until active labour started, the catheter fell out, or 12 h had elapsed. If the catheter did not fall out within 12 h, induction continued with artificial membrane rupture and oxytocin, administered through a micro-drip gravity infusion set. Fetal monitoring was by intermittent auscultation. The primary outcome was vaginal birth within 24 h. Due to the nature of the interventions, masking of participants, study investigators, and care providers to group allocation was not possible. We analysed by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01801410.

FINDINGS: Between Dec 20, 2013, and June 29, 2015, we randomly assigned 602 women to induction with misoprostol (n=302) or the Foley catheter (n=300; intention-to-treat population). Vaginal birth within 24 h was more common in women in the misoprostol group than in the Foley catheter group (172 [57·0%] vs 141 [47·0%] women; absolute risk difference 10·0%, 95% CI 2·0-17·9; p=0·0136). Rates of uterine hyperstimulation were low in both the misoprostol and Foley catheter groups (two [0·7%] vs one [0·3%] cases; absolute risk difference 0·3%, 95% CI -0·8 to 1·5; p=0·566) and neonatal deaths did not differ significantly between groups (six [2·0%] vs three [1·0%] neonatal deaths; 1·0, -1·04 to 2·97; p=0·322). 17 serious adverse events (3%) were reported during the study: one case of intrapartum convulsion and one case of disseminated intravascular coagulation (both in the Foley group); ten perinatal deaths, including two stillbirths (both in the Foley catheter group) and eight neonatal deaths (n=5 in the misoprostol group and n=3 in the Foley catheter group); and five of neonatal morbidity, comprising birth asphyxia (n=3), septicaemia (n=1), and neonatal convulsion (n=1).

INTERPRETATION: Oral misoprostol was more effective than transcervical Foley catheterisation for induction of labour in women with pre-eclampsia or hypertension. Future studies are required to assess whether oxytocin augmentation following misoprostol can be replaced by regular doses of oral misoprostol tablets.

FUNDING: Medical Research Council, Department for International Development, and Wellcome Trust Joint Global Health Trials Scheme.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Mundle S, Bracken H, Khedikar V, et al. Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India (INFORM): a multicentre, open-label, randomised controlled trial. Lancet. 2017. PMID: 28668289. doi:10.1016/S0140-6736(17)31367-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。